★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets GLP-1 Obesity Drugs Likely to Have Significant Impact on Biopharma Share Prices and Non-Healthcare Sectors The development of a new GLP-1 receptor agonist at Viking Therapeutics helped the company's shares surge by 150% this week…McAlinden Research PartnersFebruary 28, 2024
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsLabor, Education & Demographics Obesity Drug Market to Remain Heavily Concentrated Among Two Firms, Hefty US Price Tags Dominate Sales Popular GLP-1 agonists from Novo Nordisk and Eli Lilly are projected to retain a combined 80% market share among weight…McAlinden Research PartnersFebruary 20, 2024
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsManufacturing & LogisticsMarkets Obesity Drugs’ Popularity Promises to Inject New Life Into Pharma Pipelines Summary: Ongoing shortages of popular obesity-fighting drugs from Novo Nordisk represent the surging popularity of medication-based intervention as treatment. Though…McAlinden Research PartnersJuly 25, 2023
★ Daily Intelligence Briefings (DIBs)Biotechnology & Healthcare Obesity’s Tipping Point: More people are Now Obese than Underweight Globally The world is seeing an escalation of obesity due to energy-sparing technology, sugary drinks, packaged or fast food, and the…McAlinden Research PartnersMarch 25, 2019
↺ Theme Adjustments★ Daily Intelligence Briefings (DIBs)Biotechnology & Healthcare As Obesity Rates Near Tipping Point, MRP Adds New Investment Theme Faced with growing demand for improved delivery of health services at lower costs, the U.S. health care industry is transitioning…McAlinden Research PartnersJune 25, 2018